Health U.S. FDA approves AbbVie’s drug for Parkinson’s disease September 26, 2026 gopalkumarthakur@gmail.com The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill Related posts: FDA finds little evidence that a drug touted by Trump can help people with autism Why lullabies work: the science behind music for sleep UN laments ‘unacceptable’ toll of 350 aid workers killed in 2025 All you need to know about: sarcoidosis
